Digital biomarkers-objective, quantifiable physiological and behavioral measures collected through digital tools-enable continuous health assessment and hold promise for precision medicine. With non-communicable diseases (NCDs) being the leading cause of morbidity and mortality worldwide, digital biomarkers can provide early detection, continuous monitoring, and individualized care. While continuous glucose monitoring in diabetes exemplifies successful clinical translation, most digital biomarkers across internal medicine, neurology, and mental health remain in early validation stages. Moving from research feasibility to routine clinical implementation faces critical barriers: limited validation in diverse populations, lack of interoperability, insufficient integration with electronic health records, and challenges in multimodal data synthesis. Transparent, interpretable algorithms and clear regulatory pathways remain underdeveloped, while equity concerns persist as infrastructure, affordability, and capacity-building needs vary globally. This review examines advances of digital biomarkers across NCD domains and outlines prerequisites for broader adoption: rigorous multicenter validation demonstrating clinical utility, standardized interfaces, open data models, secure infrastructures with robust ethical frameworks, patient empowerment through health literacy and actionable feedback, and equitable design. Coordinated efforts are needed to bridge the gap between consumer self-tracking and clinically validated, guideline-compatible digital biomarkers. Addressing these implementation challenges is essential to enable digital biomarkers to improve prevention, diagnosis, and management of NCDs.
Agha-Mir-Salim et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: